Screener / SEC EDGAR /CIK 0000883984 /10-K filed Feb 19, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Medical Instruments

ICU Medical Inc ICUI

First person pronouns used in this Annual Report on Form 10-K, such as “we,” “us,” and “our,” refer to ICU Medical, Inc. (“ICU”) and its subsidiaries unless context requires otherwise. 10-K, Item 1

Employees
13,000
Headquarters
San Clemente, CA
CEO
Vivek Jain
Next results
around Feb 18, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $2.2B through the costs to a net profit of $732K · income statement of the 10-K

2% operating margin
Revenue to Gross profit: $822.0MRevenue to Cost of revenue: $1.4BGross profit to Operating profit: $42.8MGross profit to Operating expenses: $779.2MOperating profit to Net profit: $732KOperating profit to Tax & other: $42.1MOperating expenses to R&D: $87.5MOperating expenses to Sales, admin & other: $691.7M Revenue: $2.2B REVENUE $2.2B −6% Y/Y Gross profit: $822.0M · 37% margin GROSS PROFIT $822.0M 37% margin · +0% Y/Y Cost of revenue: $1.4B · 63% of revenue COST OF REVENUE $1.4B 63% of revenue Operating profit: $42.8M · 2% margin OPERATING PROFIT $42.8M 2% margin · +0% Y/Y Operating expenses: $779.2M · 35% of revenue OPERATING EXPENSES $779.2M 35% of revenue Net profit: $732K · 0% margin NET PROFIT $732K 0% margin Tax & other: $42.1M · 2% of revenue TAX & OTHER $42.1M 2% of revenue R&D: $87.5M · 4% of revenue R&D $87.5M 4% of revenue Sales, admin & other: $691.7M · 31% of revenue SALES, ADMIN & OTHER $691.7M 31% of revenue
Gross profit $822.0M 37% margin · +0% Y/Y
Operating profit $42.8M 2% margin · +0% Y/Y
Net profit $732K 0% margin
The full income statement, year by year

ICUI among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: -6.3%, above 4% of 154 peers (their median 10.5%) REVENUE GROWTH -6.3% · above 4% Gross margin: 40.3%, above 22% of 107 peers (their median 63.8%) GROSS MARGIN 40.3% · above 22% Operating margin: 5.1%, above 40% of 138 peers (their median 10.2%) OPERATING MARGIN 5.1% · above 40% Net margin: 1.4%, above 35% of 153 peers (their median 6.8%) NET MARGIN 1.4% · above 35% FCF margin: 9.6%, above 48% of 144 peers (their median 10.1%) FCF MARGIN 9.6% · above 48% Return on capital: 0.6%, above 1% of 89 peers (their median 9.2%) RETURN ON CAPITAL 0.6% · above 1%
ICUI Peer median Below the median

What changed

13 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 19, 2026 against Feb 27, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Inventory growing faster than revenue
    Inventory +5.3% ($584.7M to $615.9M) vs revenue -6.3% ($2.4B to $2.2B), +11.7 pts apart
  • Receivables -1.3% ($182.8M to $180.5M) vs revenue -6.3% ($2.4B to $2.2B), +5.1 pts apart
9 more checks with nothing to note
  • Cash from operations $179.8M vs net income $732,000 (FY ending Dec 31, 2025)
  • Same auditor in both 10-Ks: DELOITTE & TOUCHE LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Revenue Recognition - Chargeback Reserve
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

13 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.

All 13 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    We derive a significant portion of our revenues from non-U.S. sales and from products manufactured at our non-U.S. facilities which are then imported to the U.S. We are therefore subject to risks of doing business in other countries, including those related to tariffs, retaliatory counter measures and further escalation of trade…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    In addition, modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of a PMA. The FDA requires every manufacturer to make this determination in the first…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    Foreign data protection laws, including the European Union General Data Protection Regulation (the "EU GDPR") and the United Kingdom General Data Protection Regulation (the "UK GDPR") (the EU GDPR and UK GDPR together referred to as the "GDPR", may also apply to health-related and other personal data obtained outside of the U.S. or in…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers, which went into effect on April 1, 2013, and will remain in effect through 2032, with…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$2.3B$2.3B$2.4B$2.2B
Net income−$74.3M−$29.7M−$117.7M$732K
Operating cash flow−$62.1M$166.2M$204.0M$179.8M
Free cash flow−$152.4M$82.3M$124.7M$91.8M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$2.2B ▼ 6.3% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

3 filings in the last 30 days · SEC EDGAR

All filings

About the company

ICU Medical Inc, San Clemente, CA · from the 10-K filed Feb 19, 2026

First person pronouns used in this Annual Report on Form 10-K, such as “we,” “us,” and “our,” refer to ICU Medical, Inc. (“ICU”) and its subsidiaries unless context requires otherwise. ICU develops, manufactures and sells innovative medical products used in infusion therapy, vascular access, and vital care applications. Our team is focused on providing quality, innovation and value to our clinical customers worldwide.

Headquarters
San Clemente, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 5, 2026
Incorporated in
DE

Employees, at the top of the page: "At December 31, 2025, we had approximately 13,000 employees located in over 35 countries" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 19, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ICUI/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.